A comprehensive approach to optimizing malaria prevention in pregnant women: evaluating the efficacy, cost-effectiveness, and resistance of IPTp-SP and IPTp-DP

References

• McGready R, White NJ, Nosten F. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG. 2011 Feb;118:123–4. doi: 10.1111/j.1471-0528.2010.02810.x
   PubMed Web of Science ®Google Scholar
• Menéndez C, Ferenchick E, Roman E, Bardají A, Mangiaterra V. Malaria in pregnancy: challenges for control and the need for urgent action. Lancet Glob Health. 2015 Aug;3:e438–e446. doi: 10.1016/S2214-109X(15)00041-8
   Web of Science ®Google Scholar
• Bauserman M, Conroy AL, North K, Patterson J, Bose C, Meshnick S. An overview of malaria in pregnancy. Semin Perinatol. 2019 Aug;43:282–290. doi: 10.1053/j.semperi.2019.03.018
   PubMed Web of Science ®Google Scholar
• Andronescu LR, Sharma A, Peterson I, Kachingwe M, Kachepa W, Liang Y, et al. The effect of intermittent preventive treatment of malaria during pregnancy and placental malaria on infant risk of malaria. J Infect Dis. 2022 Feb 1;225:248–256.
   PubMedGoogle Scholar
• Gutman J, Slutsker L. Malaria control in pregnancy: still a long way to go. Lancet Infect Dis. 2011 Mar;11:157–159. doi: 10.1016/S1473-3099(10)70311-X
   PubMed Web of Science ®Google Scholar
• AIDS 2020 - UNAIDS. AIDS 2020 homepage comments.20 [cited 2022 Oct 19]. Available from: https://aids2020.unaids.org/
   Google Scholar
• Olaleye A, Okusanya BO, Oduwole O, Esu E, Meremikwu M. A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. Int J Gynaecol Obstet. 2019 Jul;146:43–55. doi: 10.1002/ijgo.12835
   PubMed Web of Science ®Google Scholar
• Salman S, Davis TM, Moore B. Defining the combined benefit of intermittent preventive malaria treatment in pregnancy. Lancet Glob Health. 2020 Jul;8:e910–e911. doi: 10.1016/S2214-109X(20)30216-3
   Web of Science ®Google Scholar
• Ross LS, Fidock DA. Elucidating mechanisms of drug-resistant Plasmodium falciparum. Cell Host Microbe. 2019;26:35–47. doi: 10.1016/j.chom.2019.06.001
   PubMed Web of Science ®Google Scholar
• Hoyt J, Hill J, Achieng F, Ouma P, Kariuki S, Desai M, et al. Healthcare provider and pregnant women’s perspectives on the implementation of intermittent screening and treatment with dihydroartemisinin-piperaquine for malaria in pregnancy in western Kenya: a qualitative study. Malaria J. 2021;20:291. doi: 10.1186/s12936-021-03826-8
   PubMed Web of Science ®Google Scholar
• World Health Organization. Policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). World Health Organization; 2014 [Cited 2023 May 4]. Available from: https://www.afro.who.int/sites/default/files/2017-06/iptp-sp-updated-policy-brief-24jan2014.pdf
   Google Scholar
• Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, et al. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS one. 2010;5:e13438. doi: 10.1371/journal.pone.0013438
   PubMed Web of Science ®Google Scholar
• Fernandes S, Were V, Gutman J, Dorsey G, Kakuru A, Desai M, et al. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data. Lancet Glob Health. 2020 Dec;8:e1512–e1523.
   PubMed Web of Science ®Google Scholar
• Orobaton N, Austin AM, Abegunde D, Abdulazeez J, Aminu K. Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria. Malaria J. 2016;15:533. doi: 10.1186/s12936-016-1578-x
   PubMed Web of Science ®Google Scholar
• Daroudi R, Akbari Sari A, Nahvijou A, Faramarzi A. Cost per DALY averted in low, middle and high income countries: evidence from global burden of disease study to estimate the cost effectiveness thresholds. SSRN Electron J. 2019. doi:10.2139/ssrn.3420403.
   Google Scholar
• Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008;105:14216–14221. doi: 10.1073/pnas.0804628105
   PubMed Web of Science ®Google Scholar
• Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLOS Med. 2016;13:e1001984. doi: 10.1371/journal.pmed.1001984
   PubMed Web of Science ®Google Scholar
• Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. In: August J, Anders M, Murad F Coyle J, editors. Advances in pharmacology. Academic Press; 1996. p. 253–297. doi: 10.1016/S1054-3589(08)60952-7
   Google Scholar
• Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:864–874. doi: 10.1038/nrmicro2239
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. Pyrimethamine, sulfadoxine and pyrimethamine monograph for professionals. Drugs.com; [cited 2014 Jan 9]. Available from: https://www.drugs.com/monograph/pyrimethamine-sulfadoxine-and-pyrimethamine.html
   Google Scholar
• Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. J Exp Biol. 2003 Nov 1;206:3745–3752.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global technical strategy for malaria 2016–2030. World Health Organization; 2015 [Cited 2023 May 3]. Available from: https://www.who.int/publications/i/item/9789241564991to
   Google Scholar